ADMA Biologics (NASDAQ:ADMA) Shares Up 6.4% Following Insider Buying Activity

ADMA Biologics Inc (NASDAQ:ADMA)’s share price shot up 6.4% on Tuesday following insider buying activity. The stock traded as high as $8.39 and last traded at $8.3840. 3,932,853 shares were traded during trading, a decline of 29% from the average session volume of 5,554,766 shares. The stock had previously closed at $7.88.

Specifically, Director Jerrold B. Grossman acquired 12,500 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were bought at an average cost of $8.01 per share, for a total transaction of $100,125.00. Following the purchase, the director owned 513,884 shares in the company, valued at $4,116,210.84. This trade represents a 2.49% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on ADMA. Zacks Research lowered ADMA Biologics from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 27th. Wall Street Zen lowered ADMA Biologics from a “buy” rating to a “hold” rating in a research note on Monday, May 4th. Mizuho decreased their price objective on ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Canaccord Genuity Group decreased their price objective on ADMA Biologics from $21.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Finally, Cantor Fitzgerald reiterated a “neutral” rating on shares of ADMA Biologics in a research note on Thursday, March 26th. Two research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $19.00.

ADMA Biologics Price Performance

The firm has a market capitalization of $1.97 billion, a P/E ratio of 12.50 and a beta of 0.83. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.93 and a current ratio of 6.95. The business has a 50 day simple moving average of $11.36 and a two-hundred day simple moving average of $15.23.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.19. The business had revenue of $114.49 million for the quarter, compared to analyst estimates of $139.98 million. ADMA Biologics had a return on equity of 39.98% and a net margin of 32.43%.The company’s quarterly revenue was down .3% compared to the same quarter last year. During the same period in the prior year, the company earned $0.11 EPS. On average, sell-side analysts expect that ADMA Biologics Inc will post 0.84 EPS for the current fiscal year.

Hedge Funds Weigh In On ADMA Biologics

A number of institutional investors have recently added to or reduced their stakes in ADMA. Keebeck Wealth Management boosted its holdings in shares of ADMA Biologics by 9.7% in the 1st quarter. Keebeck Wealth Management now owns 35,459 shares of the biotechnology company’s stock worth $319,000 after purchasing an additional 3,136 shares in the last quarter. Caxton Associates LLP purchased a new position in shares of ADMA Biologics in the 1st quarter worth about $136,000. Inceptionr LLC purchased a new position in shares of ADMA Biologics in the 1st quarter worth about $193,000. Lido Advisors LLC boosted its holdings in shares of ADMA Biologics by 17.5% in the 1st quarter. Lido Advisors LLC now owns 20,107 shares of the biotechnology company’s stock worth $181,000 after purchasing an additional 3,000 shares in the last quarter. Finally, Walleye Capital LLC purchased a new position in shares of ADMA Biologics in the 1st quarter worth about $245,000. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.